Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

v3.20.4
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Series C Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Total
Beginning balance, shares at Mar. 31, 2019 2 1,316,335        
Beginning balance, value at Mar. 31, 2019 $ 2 $ 184,074 $ (169,238) $ (4,349) $ 10,489
Cumulative effect related to April 1, 2019 adoption of Accounting Standards Update (ASU) 2016-02, Leases (Topic 842)   (59) (59)
Stock based compensation related to common stock restricted stock grants, shares   835        
Stock based compensation related to common stock restricted stock grants, value 20 20
Stock-based compensation expense, net of forfeitures   272   272
Foreign currency translation adjustment   67 67
Net income (loss)   715 715
Ending balance, shares at Jun. 30, 2019 2 1,317,170        
Ending balance, value at Jun. 30, 2019 $ 2 184,366 (168,582) (4,282) 11,504
Stock based compensation related to common stock restricted stock grants, shares   834        
Stock based compensation related to common stock restricted stock grants, value 9 9
Stock-based compensation expense, net of forfeitures   124 124
Foreign currency translation adjustment   (163) (163)
Net income (loss)   (1,203) (1,203)
Ending balance, shares at Sep. 30, 2019 2 1,318,004        
Ending balance, value at Sep. 30, 2019 $ 2 184,499 (169,785) (4,445) 10,271
Stock based compensation related to common stock restricted stock grants, shares   346        
Stock based compensation related to common stock restricted stock grants, value 6 6
Stock-based compensation expense, net of forfeitures   106 106
Foreign currency translation adjustment   264 264
Common stock issued in connection with November 29, 2019 registered direct offering, shares   446,577        
Common stock issued in connection with November 29, 2019 registered direct offering, value   1,376 1,376
Net income (loss)   (1,084) (1,084)
Ending balance, shares at Dec. 31, 2019 2 1,777,483        
Ending balance, value at Dec. 31, 2019 $ 2 186,257 (170,869) (4,181) 11,209
Beginning balance, shares at Mar. 31, 2020 2 1,777,483        
Beginning balance, value at Mar. 31, 2020 $ 2 186,559 (172,246) (5,610) 8,705
Stock based compensation related to common stock restricted stock grants, shares 3,086        
Stock based compensation related to common stock restricted stock grants, value 18 18
Stock-based compensation expense, net of forfeitures 45 45
Foreign currency translation adjustment 167 167
Issuance of common stock due to warrant exercises, shares 169,167        
Issuance of common stock due to warrant exercises, value 1,490 1,490
Conversion of Series C convertible preferred stock into common stock, shares 2 17,222        
Conversion of Series C convertible preferred stock into common stock, value
Net income (loss) 240 240
Ending balance, shares at Jun. 30, 2020 1,966,958        
Ending balance, value at Jun. 30, 2020 $ 2 188,112 (172,006) (5,443) 10,665
Beginning balance, shares at Mar. 31, 2020 2 1,777,483        
Beginning balance, value at Mar. 31, 2020 $ 2 186,559 (172,246) (5,610) 8,705
Ending balance, shares at Dec. 31, 2020 2,079,059        
Ending balance, value at Dec. 31, 2020 $ 2 189,085 (172,536) (4,235) 12,316
Beginning balance, shares at Jun. 30, 2020 1,966,958        
Beginning balance, value at Jun. 30, 2020 $ 2 188,112 (172,006) (5,443) 10,665
Stock-based compensation expense, net of forfeitures   160 160
Foreign currency translation adjustment   188 188
Issuance of common stock due to options exercises, shares 74,451        
Issuance of common stock due to options exercises, value 429 429
Net income (loss)   120 120
Ending balance, shares at Sep. 30, 2020 2,041,409        
Ending balance, value at Sep. 30, 2020 $ 2 188,701 (171,886) (5,255) 11,562
Stock based compensation related to common stock restricted stock grants, shares   833        
Stock based compensation related to common stock restricted stock grants, value 3 3
Foreign currency translation adjustment   1,020 1,020
Issuance of common stock due to warrant exercises, shares   31,817        
Issuance of common stock due to warrant exercises, value   269 269
Issuance of common stock due to options exercises, shares 5,000        
Issuance of common stock due to options exercises, value 22 22
Stock based compensation related to common stock options 90 90
Net income (loss)   (650) (650)
Ending balance, shares at Dec. 31, 2020 2,079,059        
Ending balance, value at Dec. 31, 2020 $ 2 $ 189,085 $ (172,536) $ (4,235) $ 12,316